GlassScriptPhysician profile
Sean E Green
NPI 1679585517
$1,356.21
in general payments reported to CMS, 2019-2025
22 companies · $306 in 2025
The $306 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $281 · 2022: $290 · 2023: $234 · 2024: $246 · 2025: $306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $786.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $785.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $242.82 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $213.73 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $174.65 | 2021-2025 | |
| Pfizer INC. | $105.21 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $102.02 | 2022 | |
| Novo Nordisk INC | $97.26 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $78.24 | 2021-2025 | Repatha, Otezla |
| Lilly USA, LLC | $50.32 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Astellas Pharma US INC | $41.39 | 2021-2025 | Veozah |
| International Rehabilitative Sciences, INC | $37.96 | 2025 | Rs-4i Plus With Intersperse |
| Mayne Pharma Commercial LLC | $27.79 | 2025 | |
| Medtronic, INC. | $25.04 | 2024 | Intellis Adaptivestim |
| Inspire Medical Systems, INC. | $20.02 | 2024 | Inspire |
| Eisai INC. | $19.54 | 2025 | |
| Abbott Laboratories | $18.63 | 2024 | Freestyle Libre 3 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $17.09 | 2022 | |
| Phathom Pharmaceuticals, INC. | $16.18 | 2024 | Voquezna |
| Esperion Therapeutics, INC. | $15.56 | 2021 | |
| Genentech USA, INC. | $14.58 | 2021 | |
| Radius Health, INC. | $13.72 | 2025 | Tymlos |
| Smith+Nephew, INC. | $12.67 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $11.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.